121 related articles for article (PubMed ID: 14751142)
21. Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
No JH; Jo H; Kim SH; Park IA; Kang D; Lee CH; Han SS; Kim JW; Park NH; Kang SB; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():100-4. PubMed ID: 19723042
[TBL] [Abstract][Full Text] [Related]
22. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
Borgfeldt C; Casslén B; Liu CL; Hansson S; Lecander I; Astedt B
Int J Cancer; 1998 Dec; 79(6):588-95. PubMed ID: 9842966
[TBL] [Abstract][Full Text] [Related]
23. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
24. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Nalbandian A; Djakiew D
Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
[TBL] [Abstract][Full Text] [Related]
25. Expression and activation of proteases in co-cultures.
Paduch R; Kandefer-Szerszeń M
Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
27. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.
Hoskins E; Rodriguez-Canales J; Hewitt SM; Elmasri W; Han J; Han S; Davidson B; Kohn EC
Gynecol Oncol; 2011 Sep; 122(3):656-62. PubMed ID: 21676452
[TBL] [Abstract][Full Text] [Related]
28. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
[TBL] [Abstract][Full Text] [Related]
29. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
[TBL] [Abstract][Full Text] [Related]
30. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Fishman DA; Bafetti LM; Banionis S; Kearns AS; Chilukuri K; Stack MS
Cancer; 1997 Oct; 80(8):1457-63. PubMed ID: 9338470
[TBL] [Abstract][Full Text] [Related]
31. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
So J; Wang FQ; Navari J; Schreher J; Fishman DA
Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
[TBL] [Abstract][Full Text] [Related]
32. Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
van Tilborg AA; Sweep FC; Geurts-Moespot AJ; Wetzels AM; de Waal RM; Westphal JR; Massuger LF
Int J Oncol; 2014 Apr; 44(4):1394-400. PubMed ID: 24535412
[TBL] [Abstract][Full Text] [Related]
33. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
[TBL] [Abstract][Full Text] [Related]
34. Proteolysis in human breast cancer.
Garbett EA; Reed MW; Stephenson TJ; Brown NJ
Mol Pathol; 2000 Apr; 53(2):99-106. PubMed ID: 10889910
[TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Desrosiers RR; Cusson MH; Turcotte S; Béliveau R
Int J Cancer; 2005 May; 114(5):702-12. PubMed ID: 15609318
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) expression and activity during early embryo development in the cow.
Whiteside EJ; Kan M; Jackson MM; Thompson JG; McNaughton C; Herington AC; Harvey MB
Anat Embryol (Berl); 2001 Dec; 204(6):477-83. PubMed ID: 11876533
[TBL] [Abstract][Full Text] [Related]
37. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
38. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
39. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
